Invest Securities maintains its Buy rating on Affluent Medical shares, with its target price raised from 3.3 to 4.4 euros.

The analyst has updated his model following the signature of a highly structuring agreement with Edwards Lifesciences, which will improve financial visibility by an immediate €15 million and 'considerably strengthen the group's credibility with the entry of a leading player in the capital'.

In addition, 'the group has brilliantly and intelligently succeeded in enhancing the value of its Mitrale franchise, while securing its financial horizon until Q2 25', underlines Invest.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.